Europe Radiation Oncology Market Analysis 2026

Competitive Landscape of the Radiation Oncology Market

The competitive landscape of the radiation oncology market is characterized by a dynamic and rapidly evolving environment driven by continuous technological advancements and innovation. Key players in the market are focused on developing and enhancing sophisticated radiation therapy systems, such as advanced linear accelerators, proton therapy systems, and brachytherapy devices, to meet the increasing demand for precise and effective cancer treatments. Companies are also investing in research and development to integrate cutting-edge technologies like artificial intelligence and image-guided radiation therapy, which improve treatment accuracy and patient outcomes.

In October 2023, Accuray Incorporated achieved a key milestone by receiving approval from the Chinese National Medical Products Administration (NMPA) for their Tomo® C radiation therapy system. The company's strategic move underscores its commitment to extending its market presence and meeting the growing demand for disruptive radiation oncology solutions in China. (Source: https://investors.accuray.com/news-releases/news-release-details/accuray-announces-approval-tomor-c-radiation-treatment-delivery?mobile=1) In May 2023, Elekta AB announced the acquisition of Philips Healthcare's Pinnacle Treatment Planning System (TPS) patent portfolio. This strategic initiative strengthens Elekta's position in treatment planning and demonstrates the company's commitment to being the innovation leader in radiation therapies. (Source: https://ir.elekta.com/investors/press-releases/2024/elekta-further-strengthens-its-elekta-one-software-suite-with-acquisition-of-philips-treatment-planning-patent-portfolio/) In February 2023, RefleXion Medical, a therapeutic oncology company, received the first marketing clearance from the US FDA for its SCINTIX™ biology-guided radiation, a modern therapy for early and late-stage tumors. SCINTIX is the first and only radiotherapy that enables each cancer's unique biology to autonomously choose where and how much radiation to deliver, second by second, throughout treatment. The SCINTIX biologic modality detects tumor motion from all sources, including predicted motion from internal processes like breathing and digesting, as well as unexpected movement by a patient. (Source: https://reflexion.com/press-releases/reflexion-receives-fda-clearance-for-scintix-biology-guided-radiotherapy-cutting-edge-treatment-applicable-for-early-and-late-stage-cancers/) In April 2022, Elekta AB and GE Healthcare signed a global commercial collaboration agreement in radiation oncology. This partnership will empower hospitals to provide a comprehensive range of imaging treatments for cancer patients undergoing radiotherapy, enhancing their ability to deliver high-quality care. Both companies aim to address the significant demand for radiation solutions in both established and developing markets as hospitals seek more flexible and interoperable simulation and guided systems. (Source: https://ir.elekta.com/investors/press-releases/2022/elekta-and-ge-healthcare-collaborate-to-expand-access-to-precision-radiation-therapy-solutions/)